Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration

Incyte (NasdaqGS:INCY) and Genmab announced a new clinical trial collaboration targeting KRAS G12D-mutated metastatic colorectal cancer. The study will test a combination of Genmab’s bispecific antibody with Incyte’s selective KRAS G12D inhibitor in first-line treatment settings. The collaboration adds a fresh colorectal cancer program to Incyte’s pipeline that focuses on a mutation frequently found in these patients. The new KRAS G12D metastatic colorectal cancer trial is important, but it...